New study compares long-term side effects from different prostate cancer treatments
Prostate cancer therapies are improving over time. But how do the long-term side effects from the various options available today compare? Results from a newly published study are providing some valuable insights.
Investigators at Vanderbilt University and the University of Texas MD Anderson Cancer Center spent five years tracking the sexual, bowel, urinary, and hormonal status of nearly 2,000 men after they had been treated for prostate cancer, or monitored with active surveillance (which entails checking the tumor periodically and treating it only if it begins to grow). Cancers in all the men were still confined to the p...
Source: Harvard Health Blog - February 27, 2020 Category: Consumer Health News Authors: Charlie Schmidt Tags: Health Prostate Knowledge Treatments HPK Source Type: blogs
Fight Aging! Newsletter, February 24th 2020
In conclusion, taller body height at the entry to adulthood, supposed to be a marker of early-life environment, is associated with lower risk of dementia diagnosis later in life. The association persisted when adjusted for educational level and intelligence test scores in young adulthood, suggesting that height is not just acting as an indicator of cognitive reserve.
A Comparison of Biological Age Measurement Approaches
https://www.fightaging.org/archives/2020/02/a-comparison-of-biological-age-measurement-approaches/
Researchers here assess the performance of a range of approaches to measuring biologica...
Source: Fight Aging! - February 23, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Renaissance Radiologists: Meet AJ Gunn, MD
AJ Gunn, M.D. graduated magna cum laude from Brigham Young University in Provo, UT, earning a BS in exercise physiology with a minor in sociology. He then returned home to South Dakota to attend medical school at the University of South Dakota. During medical school, he participated in the competitive Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program and was awarded the Donald L. Alcott, M.D. Award for Clinical Promise. He graduated summa cum laude in 2009. He completed his diagnostic radiology residency at the Massachusetts General Hospital of Harvard Medical School in Boston, MA ...
Source: radRounds - February 21, 2020 Category: Radiology Authors: Robin Pine Miles Source Type: blogs
Renaissance Rad Feature: Meet AJ Gunn, MD
AJ Gunn, M.D. graduated magna cum laude from Brigham Young University in Provo, UT, earning a BS in exercise physiology with a minor in sociology. He then returned home to South Dakota to attend medical school at the University of South Dakota. During medical school, he participated in the competitive Howard Hughes Medical Institute – National Institutes of Health Research Scholars Program and was awarded the Donald L. Alcott, M.D. Award for Clinical Promise. He graduated summa cum laude in 2009. He completed his diagnostic radiology residency at the Massachusetts General Hospital of Harvard Medical School in Boston, MA ...
Source: radRounds - February 21, 2020 Category: Radiology Authors: Robin Pine Miles Source Type: blogs
An Interview with Lewis Gruber of SIWA Therapeutics
SIWA Therapeutics is one of the few senolytics biotech companies founded prior to the past few years, invigorated with new funding now that the clearance of senescent cells as a basis for rejuvenation is an area of intense interest for the research and development community. The company is also, I believe, running the only senolytics program based the use of monoclonal antibodies. This is a way to encourage the immune system to destroy cells bearing specific surface markers, in this case a form of advanced glycation endproduct that is found on cancerous, senescent, and otherwise dysfunctional cells.
Many of our re...
Source: Fight Aging! - February 19, 2020 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Request for Startups in the Rejuvenation Biotechnology Space, 2020 Edition
This is the latest in a series of yearly posts in which I suggest areas of development for biotech startups I'd like to see actively developed as a part of the longevity industry in the near future. Today, this year, is a good time to be starting a company focused on the production of a novel therapeutic approach to intervening in the aging process. There is a great deal of funding for seed stage investment, and many compelling projects lacking champions, yet to be carried forward from academia into preclinical development. Numerous scientific and industry crossover conferences are now held every year, at which it is possi...
Source: Fight Aging! - February 17, 2020 Category: Research Authors: Reason Tags: Investment Source Type: blogs
Genomic Profiling for Precision Medicine: Interview with David Spetzler, Caris Life Sciences
Caris Life Sciences, a Dallas-based innovator in molecular science focused on fulfilling the promise of precision medicine, has developed the MI Genomic Profiling Similarity (GPS) score to compare the molecular characteristics of specific tumors against those in the Caris database. This allows clinicians to identify the molecular subtype of their patients’ tumors and guide personalized treatment. The system is driven by machine learning algorithms and is envisaged as being particularly useful in guiding the treatment of cancers in cases where there is ambiguity about the tissue of origin and in other atypical or difficul...
Source: Medgadget - January 28, 2020 Category: Medical Devices Authors: Conn Hastings Tags: Exclusive Genetics Informatics Oncology Pathology Source Type: blogs
Fight Aging! Newsletter, January 27th 2020
Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe or unsubscribe from the newsletter,
please visit:
https://www.fightaging.org/newsletter/
Longevity Industry Consulting Services
Reason, the founder of Fight Aging! and Repair Biotechnologies, offers strategic consulting services to investors, entrepreneurs, and others interested in the longevity industry and its complexities. To find out m...
Source: Fight Aging! - January 26, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
MR1 as a Broad Signature of Cancer, Suitable for T Cell Targeting
Meaningful progress towards the control of cancer, ending it as a major threat to life and health, will be led by programs that can produce very broadly applicable treatments. That means therapies that can be applied to many (or even all) cancers with minimal differences in configuration or need for further per-cancer development. There are hundreds of cancer subtypes, but only so many researchers, and only so much funding for research and development: development of highly specific therapies is just not an effective path forward.
Examples of the most promising lines of work with broad application include the OncoSe...
Source: Fight Aging! - January 22, 2020 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Notes on the SENS Research Foundation Pitch Day, January 2020
The J.P. Morgan Healthcare conference runs every year in San Francisco, a big draw for the biotech industry, and many organizations take the opportunity to host events at the same time. Among these, the SENS Research Foundation has for the past few years hosted a pitch day in which biotech companies in the longevity industry, largely startups, present to that portion of the Bay Area investor community interested in funding the treatment of aging as a medical condition. I was there to present on progress at Repair Biotechnologies, and took some notes on the other companies as they talked about their work.
Kimera Labs
...
Source: Fight Aging! - January 20, 2020 Category: Research Authors: Reason Tags: Investment Source Type: blogs
Fight Aging! Newsletter, January 20th 2020
This study provides strong evidence that following a healthy lifestyle can substantially extend the years a person lives disease-free."
Commentary on Recent Evidence for Cognitive Decline to Precede Amyloid Aggregation in Alzheimer's Disease
https://www.fightaging.org/archives/2020/01/commentary-on-recent-evidence-for-cognitive-decline-to-precede-amyloid-aggregation-in-alzheimers-disease/
I can't say that I think the data presented in the research noted here merits quite the degree of the attention that it has been given in the popular science press. It is interesting, but not compelling if its role is ...
Source: Fight Aging! - January 19, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Cancer Mortality Rates Continue to Fall
That cancer mortality is declining at a time in which the aged segment of the population is growing, and ever more people are overweight and obese, is a testament to (a) improved prevention (largely fewer people smoking, which has a sizable impact on lung cancer incidence and severity) and (b) the ever increasing efficacy of modern cancer treatments, particularly immunotherapies. These newer cancer therapies are still in the comparatively early stages of evolution as a technology platform, and we should expect these gains to continue. The immunotherapies of the 2030s will be very impressive in comparison to those deployed ...
Source: Fight Aging! - January 17, 2020 Category: Research Authors: Reason Tags: Daily News Source Type: blogs
Fight Aging! Newsletter, January 6th 2020
Conclusion
A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - January 5, 2020 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
A Look Back at 2019: Progress Towards the Treatment of Aging as a Medical Condition
Conclusion
A great deal of progress is being made in the matter of treating aging: in advocacy, in funding, in the research and development. It can never be enough, and it can never be fast enough, given the enormous cost in suffering and lost lives. The longevity industry is really only just getting started in the grand scheme of things: it looks vast to those of us who followed the slow, halting progress in aging research that was the state of things a decade or two ago. But it is still tiny compared to the rest of the medical industry, and it remains the case that there is a great deal of work yet to be done at all...
Source: Fight Aging! - December 31, 2019 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs
16 fold higher risk of cancer with peripartum cardiomyopathy
German cancer registry (Robert-Koch-Institute) data has shown a 16 fold risk of cancer in those with peripartum cardiomyopathy [1]. According to the report 21 of 236 patients had cancer, of which 12 had cancer diagnosed before peripartum cardiomyopathy. 11 of them had cardiotoxic chemotherapy. Of these, 17% fully recovered cardiac function compared to 55% of peripartum cardiomyopathy patients without cancer. Of the 10 patients who developed cancer after peripartum cardiomyopathy, 80% had left ventricular ejection fraction of 50% or more after cancer therapy. Authors mention that the high prevalence could be due to geneti...
Source: Cardiophile MD - December 23, 2019 Category: Cardiology Authors: Prof. Dr. Johnson Francis Tags: Cardio Oncology Source Type: blogs
